The updated price target and maintained rating reflect BMO Capital's confidence in Disc Medicine's progress ... the company holds more cash than debt on its balance sheet, which could provide ...

This aligns with the positive sentiment surrounding the bitopertin regulatory update and the increased price target. Despite these gains, InvestingPro Tips indicate that Disc Medicine is not currently ...

HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a report on Tuesday. Jefferies Financial Group initiated coverage on Disc Medicine in a ...

Rather than the typical approach of striking a ball with a club, participants of this golf variant aim to fling a disc towards a designated target. A game usually consists of 9 or 18 holes but ...

BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $112 from $70 and keeps an Outperform rating on the shares. Following the “positive” regulatory update for bitopertin ...

BMO Capital Markets revised its outlook, raising the price target to $70 from $50. Furthermore ... However, it's worth noting that Disc Medicine holds more cash than debt on its balance sheet, ...